Academic Journal
The efficacy and safety of ombitasvir/paritaprevir/ritonavir plus ribavirin in hepatitis C virus-infected patients with end-stage renal disease on regular hemodialysis
| العنوان: | The efficacy and safety of ombitasvir/paritaprevir/ritonavir plus ribavirin in hepatitis C virus-infected patients with end-stage renal disease on regular hemodialysis |
|---|---|
| المؤلفون: | Muhammad M A. Ghaffar, Dalia Omran, Enass El Sayed |
| المصدر: | Journal of Medicine in Scientific Research, Vol 4, Iss 2, Pp 170-175 (2021) |
| بيانات النشر: | General Organization of Teaching Hospitals and Institutes, 2021. |
| سنة النشر: | 2021 |
| المجموعة: | LCC:Medicine |
| مصطلحات موضوعية: | chronic hepatitis c virus, direct-acting antiviral therapy, efficacy, hemodialysis, ombitasvir/paritaprevir/ritonavir combination therapy, safety, sustained virological response, treatment, Medicine |
| الوصف: | Background and aim Infection with hepatitis C virus (HCV) is an important cause of mortality and morbidity in patients with end-stage renal disease. Direct-acting antiviral drugs allow for the treatment of this group of patients. The current research aims to assess the efficacy and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/RTV) combination therapy plus ribavirin in the treatment of HCV-infected Egyptian patients with chronic kidney disease stage V on regular hemodialysis. Patients and methods A total of 70 patients with chronic kidney disease stage V on regular hemodialysis with HCV infection were enrolled in this prospective cohort study, where 37 patients (group A) received OBV/PTV/RTV combination therapy plus ribavirin for 12 weeks. The remaining 33 patients (group B) refused treatment. The sustained virologic response and the adverse events were monitored. Results A total of 35 patients of group A [35/37 (94.6%)] completed 12 weeks of HCV therapy, and all of them [35/35 (100%)] achieved sustained virologic response 12. The patients suitably tolerated the therapy. Pruritis (65.7%), anemia (62.9%), gastrointestinal tract manifestations (60%), and fatigue (35%) were the most frequently reported adverse effects. There was a nonsignificant decrease in the hemoglobin and the hematocrit values in the treatment group. Conclusion OBV/PTV/RTV combination therapy plus ribavirin can be used safely and effectively in the treatment of chronic HCV-infected patients on regular hemodialysis. The drug combination is safe and tolerable. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2537-091X 2537-0928 |
| Relation: | http://www.jmsr.eg.net/article.asp?issn=2537-091X;year=2021;volume=4;issue=2;spage=170;epage=175;aulast=A.; https://doaj.org/toc/2537-091X; https://doaj.org/toc/2537-0928 |
| DOI: | 10.4103/jmisr.jmisr_114_20 |
| URL الوصول: | https://doaj.org/article/0ecbcbf83bae4496a999ea7b672e540c |
| رقم الانضمام: | edsdoj.0ecbcbf83bae4496a999ea7b672e540c |
| قاعدة البيانات: | Directory of Open Access Journals |
| تدمد: | 2537091X 25370928 |
|---|---|
| DOI: | 10.4103/jmisr.jmisr_114_20 |